Cargando...
Initial apixaban dosing in patients with atrial fibrillation
BACKGROUND: Apixaban is a non–vitamin K oral anticoagulant approved for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). Current labeling recommends dose reduction based on patient age, weight, and renal function. HYPOTHESIS: The aim of this study was...
Guardado en:
| Publicado en: | Clin Cardiol |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Wiley Periodicals, Inc.
2018
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6489803/ https://ncbi.nlm.nih.gov/pubmed/29542830 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.22949 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|